Doximity Inc
NYSE:DOCS
Doximity Inc
Doximity Inc., often regarded as the social network for doctors, has carved a unique niche for itself by seamlessly blending the culture of community with professional networking specifically tailored for the medical field. Founded in 2010 by Jeff Tangney, a co-founder of Epocrates, Doximity leverages technology to connect healthcare professionals nationwide, offering tools for both communication and collaboration. Much like LinkedIn, but with a focus on physicians and clinicians, Doximity provides a platform where medical practitioners can securely connect with colleagues, stay informed about the latest developments in their fields, and peruse professional opportunities. Its services cater not just to social networking, but also to telemedicine, reflecting the modern demands of a rapidly digitizing healthcare landscape.
The company monetizes primarily through three main revenue streams: pharmaceutical marketing, hiring solutions, and telehealth services. Pharmaceutical companies pay Doximity for targeted marketing opportunities, allowing them to reach specific segments of the medical community with precision and impact. Additionally, hospitals and medical groups subscribe to its hiring solutions to recruit top-tier medical talent. In an era where telemedicine has become increasingly vital, Doximity’s telehealth solutions have gained traction, enabling physicians to engage in virtual consultations efficiently. This multi-faceted business model allows Doximity to stay at the forefront of digital healthcare services, driving growth while serving a highly specialized market.
Doximity Inc., often regarded as the social network for doctors, has carved a unique niche for itself by seamlessly blending the culture of community with professional networking specifically tailored for the medical field. Founded in 2010 by Jeff Tangney, a co-founder of Epocrates, Doximity leverages technology to connect healthcare professionals nationwide, offering tools for both communication and collaboration. Much like LinkedIn, but with a focus on physicians and clinicians, Doximity provides a platform where medical practitioners can securely connect with colleagues, stay informed about the latest developments in their fields, and peruse professional opportunities. Its services cater not just to social networking, but also to telemedicine, reflecting the modern demands of a rapidly digitizing healthcare landscape.
The company monetizes primarily through three main revenue streams: pharmaceutical marketing, hiring solutions, and telehealth services. Pharmaceutical companies pay Doximity for targeted marketing opportunities, allowing them to reach specific segments of the medical community with precision and impact. Additionally, hospitals and medical groups subscribe to its hiring solutions to recruit top-tier medical talent. In an era where telemedicine has become increasingly vital, Doximity’s telehealth solutions have gained traction, enabling physicians to engage in virtual consultations efficiently. This multi-faceted business model allows Doximity to stay at the forefront of digital healthcare services, driving growth while serving a highly specialized market.
Revenue Beat: Doximity reported Q3 revenue of $185 million, up 10% year-over-year and exceeding the high end of guidance by 2%.
Strong Profitability: Adjusted EBITDA was $111 million with a 60% margin, also above guidance.
Record User Engagement: The platform surpassed 3 million registered members, representing over 85% of all U.S. physicians, with record active usage of workflow and AI products.
AI Adoption: Over 300,000 unique prescribers used Doximity's AI tools in Q3, and the company signed 100+ major health systems for its AI suite.
Guidance Unchanged: Despite Q3 outperformance, full-year guidance remains in line due to subdued Q4 expectations and higher AI infrastructure costs.
Pharma Budget Uncertainty: Delays in pharma clients' budget decisions, driven by new policy (MFN agreements), led to a slower Q4 revenue outlook but strong January bookings.
Optimistic Outlook: Management expects revenue growth to accelerate later in the year, aiming to exit calendar 2026 with double-digit growth and to commercialize AI products.
